Merck receives Breakthrough Therapy Designation from FDA and PRIME status from EMA for investigational Ebola Zaire vaccine (V920)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, has announced two regulatory milestones for the company's investigational vaccine for Ebola Zaire, V920 (rVSV∆G-ZEBOV-GP, live attenuated): the U.S. Food and Drug Administration (FDA) has granted the vaccine candidate Breakthrough Therapy Designation, and the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) status.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Merck Business and Industry Source Type: news